[thim-heading title=”FetalDNA Basic” title_uppercase=”” textcolor=”#f2483e” size=”h4″ title_custom=”custom” font_weight=”” sub_heading_color=”#f2483b” clone_title=”” line=”true” text_align=”text-center”]

This NIPT investigates the most common forms of chromosomal abnormalities, the 21 (Down syndrome) 18 (Edward syndrome) and the 13 (Patau syndrome). This is the test recommended by all Guidelines and Scientific Societies.

You can know, on demand, the sex of the unborn child. No information is provided on the other chromosomal abnormalities, including sexual ones. Although this test guarantees maximum reliability because it always performs a check in Digital PCR, methodology that has a very high sensitivity, it is (as for all NIPT), always a screening test and non-diagnostic.

This latest test should be added, as indicated by the Guidelines, to the ultrasound study of the nuchal translucency and represents an overcoming of the traditional combined tests included in the first trimester screening (e.g. Bi-Test, Tri-Test, etc.).

This examination has very low costs for the patient and a very speedy response.

On request can be provided, as mentioned, also fetal sex but not sex chromosome abnormalities. For screening of other chromosomal and genetic alterations, other more advanced NIPT tests (Basic Plus FetalDNA, Karyotype, Karyotype Plus) should be used. Diagnostic certainty is provided only by invasive tests (Amniocentesis or CVS Test) as reported in all Guidelines and in international literature.
Reporting times are included within 5 working days but may increase in case of technical difficulties on DNA analysis or if the test should be repeated.

NB: If the DNA screening test (INIPT Mini) provides a pathological result, the Center offers, for free, the confirmation test through prenatal diagnosis CVS Test or Amniocentesis, at the Main Center Altamedica in Rome.

To compare the various NIPT tests available go to: www.fetaldna.it/en/fetal-dna

or explore the table below: